Molecular Markers of Glial Tumors: Current Targeting Strategies

Samoylova, Tatiana I.; Morrison, Nancy E.; Cox, Nancy R.

doi:10.2174/0929867033457737

Cited by 6 publications

(6 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical diagnosis of brain tumor is mainly bases on imaging techniques, but sometimes there is still need to identify the characteristic of the lesions, especially before treatment. Unfortunately, the biomarkers for qualitative diagnosis of brain tumor are lacking (DeAngelis, 2001;Samoylova et al, 2003). In the study, we screened 22 biomarkers for identification of glioma from brain benign tumors whose sensitivity and specificity were 88.9% and 86.4% respectively.…”

Section: Discussionmentioning

confidence: 99%

Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor

Liu

Zheng

et al. 2005

J Zheijang Univ Sci B

View full text Add to dashboard Cite

To screen and evaluate protein biomarkers for the detection of gliomas (Astrocytoma grade I-IV) from healthy individuals and gliomas from brain benign tumors by using surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) coupled with an artificial neural network (ANN) algorithm. SELDI-TOF-MS protein fingerprinting of serum from 105 brain tumor patients and healthy individuals, included 28 patients with glioma (Astrocytoma I-IV), 37 patients with brain benign tumor, and 40 age-matched healthy individuals. Two thirds of the total samples of every compared pair as training set were used to set up discriminating patterns, and one third of total samples of every compared pair as test set were used to cross-validate; simultaneously, discriminate-cluster analysis derived SPSS 10.0 software was used to compare Astrocytoma grade I-II with grade III-IV ones. An accuracy of 95.7%, sensitivity of 88.9%, specificity of 100%, positive predictive value of 90% and negative predictive value of 100% were obtained in a blinded test set comparing gliomas patients with healthy individuals; an accuracy of 86.4%, sensitivity of 88.9%, specificity of 84.6%, positive predictive value of 90% and negative predictive value of 85.7% were obtained when patient's gliomas was compared with benign brain tumor. Total accuracy of 85.7%, accuracy of grade I-II Astrocytoma was 86.7%, accuracy of III-IV Astrocytoma was 84.6% were obtained when grade I-II Astrocytoma was compared with grade III-IV ones (discriminant analysis). SELDI-TOF-MS combined with bioinformatics tools, could greatly facilitate the discovery of better biomarkers. The high sensitivity and specificity achieved by the use of selected biomarkers showed great potential application for the discrimination of gliomas patients from healthy individuals and gliomas from brain benign tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor

Liu

Zheng

et al. 2005

J Zheijang Univ Sci B

View full text Add to dashboard Cite

show abstract

“…Two peptides selected in this screening were different by their ability to penetrate cellular membrane [66]. Several peptides that were able to selectively bind the surface of malignant glial cells, have been isolated from landscape type random peptide phage library [67]. Most of the isolated peptides revealed surface binding, whereas some peptides, in addition, were able to cross cellular membrane [67].…”

Section: Cell-specific Targetingmentioning

confidence: 99%

“…Several peptides that were able to selectively bind the surface of malignant glial cells, have been isolated from landscape type random peptide phage library [67]. Most of the isolated peptides revealed surface binding, whereas some peptides, in addition, were able to cross cellular membrane [67]. Another peptide MCPKH-PLGC, which specifically targeted the surfaces of human malignant glioma cell lines was selected from CMTI phage -displayed library [68].…”

Section: Cell-specific Targetingmentioning

confidence: 99%

Identification of Tumor Targeting Agents by Phage Display

Romanov¹

2005

MCRO

View full text Add to dashboard Cite

Techniques of the phage display libraries construction have been dramatically improved. This allowed researchers to expand the application field to cancer biology. Tumor targeting -selective delivery of active compounds to the tumor sites for cancer imaging or treatment presents obvious advantages as compared to chemotherapeutic approachkilling rapidly proliferating cells. Tumor-avid peptides can be efficiently identified by means of phage display libraries.The most direct application of peptide-protein phage-displayed libraries is a selection of ligands for individual molecules important for cancer development. This includes identification of ligands for cell surface molecules, mapping proteinprotein interactions and delineation of signal transduction pathways. Enzymes substrates and modulators of their activity can also be identified via phage display-based selection. Recently, more complicated than individual molecules, biological systems started to be used as targets for biopanning. This includes combination of soluble proteins, cellular surfaces and even vasculature or surface of whole organs. In addition, construction and application of cDNA expression libraries in phage-based vectors recently received appreciation. The use of the phage as a vector for targeted gene therapy is also considered. In the current review, we will discuss the selection of tumor-targeting peptides and proteins identified by means of random peptide and cDNA phage-displayed libraries.

show abstract

“…Malignant gliomas are fatal brain tumors composed of heterogeneic cells expressing molecular markers that differ not only from patient to patient but also from cell to cell within the tumor mass. Cell heterogeneity and a limited number of truly glioma-specific receptors identified thus far (5,6) are among those factors that prevent the development of targeting cytotoxic agents that are effective in the majority of patients (7). …”

Section: Introductionmentioning

confidence: 99%

Phage matrix for isolation of glioma cell membrane proteins

et al. 2004

View full text Add to dashboard Cite

Cell-binding ligands for RG2 rat glioma were identified in our recent study from a library of peptides that are displayed as fusion molecules on phage particles. Here, one of the phage clones was used to affinity purify those cell membrane components to which the displayed peptides bind. This phage clone, displaying the ELRGDSLP peptide, was shown to recognize glioma cells specifically in comparison to control phage-expressing peptides of either similar or irrelevant sequences. Blocking experiments with synthetic RGDS peptide demonstrated that the phage-glioma cell recognition occurs via the RGD motif known to be present in many integrin-binding proteins. To form an affinity matrix that would bind to glioma cell membrane molecules, ELRGDSLP phage particles were cross-linked using dextran polymer. Whole cell lysate from RG2 rat glioma cells was passed through the matrix, resulting in the isolation of cell membrane components having strong affinity to the peptides on phage and molecules associated with those components. One of the isolated proteins was found to be CD44s, a cell surface adhesion molecule involved in glioma cell invasion and migration, which likely formed a complex with an RGD-binding integrin. Cell membrane proteins isolated with this innovative approach could be used for the design of cell-specific anticancer treatments.

show abstract

Molecular Markers of Glial Tumors: Current Targeting Strategies

Cited by 6 publications

References 106 publications

Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor

Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor

Identification of Tumor Targeting Agents by Phage Display

Phage matrix for isolation of glioma cell membrane proteins

Contact Info

Product

Resources

About